DYN Dyne Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DYN

Price (delayed)

$26.08

Market cap

$2.28B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.97

Enterprise value

$2.03B

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in ...

Highlights
The equity has soared by 98% YoY
Dyne Therapeutics's quick ratio has soared by 83% YoY
DYN's net income is down by 46% YoY and by 9% QoQ
DYN's EPS is down by 20% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.dyne-tx.com
Peers: NRG AES ALE CNP

Key stats

What are the main financial stats of DYN
Market
Shares outstanding
87.38M
Market cap
$2.28B
Enterprise value
$2.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$257.4M
EBITDA
-$255M
Free cash flow
-$220.48M
Per share
EPS
-$3.97
Free cash flow per share
-$2.72
Book value per share
$5.83
Revenue per share
$0
TBVPS
$6.44
Balance sheet
Total assets
$522.28M
Total liabilities
$44.22M
Debt
$26.62M
Equity
$478.06M
Working capital
$465.78M
Liquidity
Debt to equity
0.06
Current ratio
21.83
Quick ratio
20.37
Net debt/EBITDA
0.97
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-90%
Return on equity
-110.9%
Return on invested capital
-238.6%
Return on capital employed
-51.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DYN stock price

How has the Dyne Therapeutics stock price performed over time
Intraday
0.31%
1 week
5.46%
1 month
-9.32%
1 year
116.07%
YTD
96.09%
QTD
-8.14%

Financial performance

How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$265.85M
Net income
-$257.4M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 47% YoY and by 10% QoQ
DYN's net income is down by 46% YoY and by 9% QoQ

Growth

What is Dyne Therapeutics's growth rate over time

Valuation

What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
4.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is down by 20% year-on-year
The equity has soared by 98% YoY
The price to book (P/B) is 12% lower than the last 4 quarters average of 5.1

Efficiency

How efficient is Dyne Therapeutics business performance
DYN's return on invested capital has dropped by 110% year-on-year but it is up by 26% since the previous quarter
The return on equity has dropped by 62% year-on-year but it is up by 19% since the previous quarter
The company's return on assets has shrunk by 57% YoY but it rose by 13% QoQ

Dividends

What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DYN.

Financial health

How did Dyne Therapeutics financials performed over time
Dyne Therapeutics's current ratio has soared by 89% YoY
Dyne Therapeutics's quick ratio has soared by 83% YoY
The debt is 94% smaller than the equity
The equity has soared by 98% YoY
Dyne Therapeutics's debt to equity has shrunk by 80% QoQ and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.